![Study design with overlapping SAD-MAD cohorts, where treatment periods... | Download Scientific Diagram Study design with overlapping SAD-MAD cohorts, where treatment periods... | Download Scientific Diagram](https://www.researchgate.net/profile/Chad-Swanson/publication/299547400/figure/fig1/AS:614240520007685@1523457760729/Study-design-with-overlapping-SAD-MAD-cohorts-where-treatment-periods-took-place-in-a_Q320.jpg)
Study design with overlapping SAD-MAD cohorts, where treatment periods... | Download Scientific Diagram
![Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 | Trials | Full Text Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-021-05538-5/MediaObjects/13063_2021_5538_Fig1_HTML.png)
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 | Trials | Full Text
On Biostatistics and Clinical Trials: SAD and MAD: Single Ascending Dose and Multiple Ascending Dose first-in-human studies
![Figure 1 from A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial | Semantic Scholar Figure 1 from A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2c81e876d3abfcd4197eca4f4fd501dfcf9ea2bf/3-Figure1-1.png)
Figure 1 from A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial | Semantic Scholar
![Single and multiple ascending dose GS-9256 and GS-9451 clinical trial... | Download Scientific Diagram Single and multiple ascending dose GS-9256 and GS-9451 clinical trial... | Download Scientific Diagram](https://www.researchgate.net/profile/Hongmei-Mo/publication/230573915/figure/fig1/AS:300770919501828@1448720783688/Single-and-multiple-ascending-dose-GS-9256-and-GS-9451-clinical-trial-designs.png)
Single and multiple ascending dose GS-9256 and GS-9451 clinical trial... | Download Scientific Diagram
On Biostatistics and Clinical Trials: SAD and MAD: Single Ascending Dose and Multiple Ascending Dose first-in-human studies
![Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults | Antimicrobial Agents and Chemotherapy Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults | Antimicrobial Agents and Chemotherapy](https://journals.asm.org/cms/10.1128/AAC.00523-15/asset/7deb3c55-3a9e-49db-8263-0f738cee8f75/assets/graphic/zac0081542490001.jpeg)
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults | Antimicrobial Agents and Chemotherapy
![Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection | British Journal of Cancer Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2017.473/MediaObjects/41416_2018_Article_BFbjc2017473_Fig1_HTML.jpg)